Type 2 Diabetes Clinical Trial
Official title:
The Effects of High and Low GI Breakfasts on Cognitive Performance in Adults With Type 2 Diabetes
Consumption of a low glycemic index (GI) diet has been shown to improve glycaemic control in
type 2 diabetics(Brand−Miller et al., 2003; Jenkins et al., 2008). In addition to the
benefits for glycaemic control there is some evidence for acute improvements in cognitive
performance after consumption of low GI foods compared with high GI foods in both adults
(Benton et al., 2003; Kaplan et al., 2000) and adolescents (Ingwersen et al., 2007; Smith
and Foster, 2008).
Given these findings it is possible that low GI focused dietary interventions designed to
improve glycaemic control and health outcomes for diabetic patients could also improve the
cognitive function of these patients. This is of particular relevance in light of the
evidence associating type 2 diabetes with cognitive decrements (Awad et al., 2004; Stewart
and Loilitsa 1999; van Harten et al., 2006). To date two studies with type 2 diabetics have
reported that a low GI breakfast was associated with increased verbal memory performance
compared to a high GI breakfast (Greenwood et al., 2003; Papanikolaou et al. 2006). Further
research should investigate the benefit of low GI foods to cognition.
The aim of this study is to examine the effects of high and low glycaemic index breakfast on
cognitive performance in adults with type 2 diabetes. Participants will perform a battery of
cognitive tests after consuming 3 different breakfasts (high GI, low GI, and water) on 3
different tests days. The participants will be recruited from the general public and from
the Leeds Teaching Hospital diabetes clinic.
This research can benefit the development of specific dietary behaviours aimed at reducing
diabetes related cognitive decline. This research is part of a PhD funded by the Economic
and Social Research Council and the University of Leeds.
| Status | Recruiting |
| Enrollment | 50 |
| Est. completion date | September 2010 |
| Est. primary completion date | March 2010 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Able to give informed consent - Type 2 diabetes - White British or White North American ethnicity and native English speakers - Not previously received or currently received subcutaneous insulin as part of their diabetes treatment. - Vision sufficiently good to complete the cognitive testing (using glasses and/or lenses). Exclusion Criteria: - Dementia (as indicated using the Mini Mental State Examination <26) - Current (or recent i.e. in last 6 months) cigarette smoker - Neurological disorder - Previous stroke - Medication other than diabetes treatment medication that has a direct effect on the brain and is likely to influence cognitive function. Co-existent diabetic complications will not be considered exclusion criteria unless they result in inability to complete the cognitive testing (e.g. insufficient vision). These exclusion criteria have been chosen on the basis that these are factors that can affect cognitive performance. Given that the cognitive tests involve learning English words, only participants who have English as their first language can be included because different cognitive processes are used when learning in a non-native language (Wong et al., 2004). Ethnicity can influence glucose regulation and risk of diabetes. Given that part of this research is examining the relationship between glucose regulation and cognition it is important that potential confounds such as ethnicity/genetic propensity to diabetes are controlled for. |
Observational Model: Case Control, Time Perspective: Cross-Sectional
| Country | Name | City | State |
|---|---|---|---|
| United Kingdom | Institute of Psychological Sciences, University of Leeds, UK | Leeds | West Yorkshire |
| Lead Sponsor | Collaborator |
|---|---|
| University of Leeds |
United Kingdom,
Awad N, Gagnon M, Messier C. The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol. 2004 Nov;26(8):1044-80. Review. — View Citation
Benton D, Ruffin MP, Lassel T, Nabb S, Messaoudi M, Vinoy S, Desor D, Lang V. The delivery rate of dietary carbohydrates affects cognitive performance in both rats and humans. Psychopharmacology (Berl). 2003 Feb;166(1):86-90. Epub 2002 Dec 12. — View Citation
Brand-Miller J, Hayne S, Petocz P, Colagiuri S. Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials. Diabetes Care. 2003 Aug;26(8):2261-7. — View Citation
Greenwood CE, Kaplan RJ, Hebblethwaite S, Jenkins DJ. Carbohydrate-induced memory impairment in adults with type 2 diabetes. Diabetes Care. 2003 Jul;26(7):1961-6. — View Citation
Ingwersen J, Defeyter MA, Kennedy DO, Wesnes KA, Scholey AB. A low glycaemic index breakfast cereal preferentially prevents children's cognitive performance from declining throughout the morning. Appetite. 2007 Jul;49(1):240-4. Epub 2007 Jan 16. — View Citation
Jenkins DJ, Kendall CW, McKeown-Eyssen G, Josse RG, Silverberg J, Booth GL, Vidgen E, Josse AR, Nguyen TH, Corrigan S, Banach MS, Ares S, Mitchell S, Emam A, Augustin LS, Parker TL, Leiter LA. Effect of a low-glycemic index or a high-cereal fiber diet on type 2 diabetes: a randomized trial. JAMA. 2008 Dec 17;300(23):2742-53. doi: 10.1001/jama.2008.808. — View Citation
Kaplan RJ, Greenwood CE, Winocur G, Wolever TM. Cognitive performance is associated with glucose regulation in healthy elderly persons and can be enhanced with glucose and dietary carbohydrates. Am J Clin Nutr. 2000 Sep;72(3):825-36. — View Citation
Papanikolaou Y, Palmer H, Binns MA, Jenkins DJ, Greenwood CE. Better cognitive performance following a low-glycaemic-index compared with a high-glycaemic-index carbohydrate meal in adults with type 2 diabetes. Diabetologia. 2006 May;49(5):855-62. Epub 2006 Mar 1. — View Citation
Smith MA, Foster JK. The impact of a high versus a low glycaemic index breakfast cereal meal on verbal episodic memory in healthy adolescents. Nutr Neurosci. 2008 Oct;11(5):219-27. doi: 10.1179/147683008X344110. — View Citation
Stewart R, Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med. 1999 Feb;16(2):93-112. Review. — View Citation
van Harten B, de Leeuw FE, Weinstein HC, Scheltens P, Biessels GJ. Brain imaging in patients with diabetes: a systematic review. Diabetes Care. 2006 Nov;29(11):2539-48. Review. — View Citation
Wong PC, Parsons LM, Martinez M, Diehl RL. The role of the insular cortex in pitch pattern perception: the effect of linguistic contexts. J Neurosci. 2004 Oct 13;24(41):9153-60. — View Citation
* Note: There are 12 references in all — Click here to view all references
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Cognitive performance (e.g. memory, attention, reaction time, and problem solving ability). | The primary outcome is measured on three occasions during the three conditions | No | |
| Primary | Blood glucose levels | These are measured during of each of the three conditions | No | |
| Secondary | Subjective sensations of appetite, mood, and mental alertness | These are measured during all three conditions | No | |
| Secondary | Sleep quality | This is measured prior to each of the three test days and at the screening visit | No | |
| Secondary | Stress levels | This is measured prior to each of the three test days and at the screening visit | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
| Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
| Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
| Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
| Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
| Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
| Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
| Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
| Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
| Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
| Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
| Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |